Astragaloside IV targeting autophagy of T cells improves inflammation of asthma.
Qing-Qing YangHong-Ying ZhangXiao-Hong DuanMi-Hui LiJing SunLi-Xia TianJing-Cheng DongLing-Wen KongPublished in: Journal of Asian natural products research (2024)
Astragaloside IV (AST) has been confirmed to have antiasthmatic effects. However, the underline mechanism is unclear. The study aimed to explore the treatment mechanism of AST based on autophagy of memory T cells. AST treatment significantly decreased the number of T effector cells in asthma mice blood and the nude mice that received AST-treated T CM s had relieved inflammation compared with the untreated group; meanwhile, we found that AST significantly decreased the autophagy level and inhibited OX40/OX40L signal pathway of lymphocytes. The results highlighted that AST regulated autophagy to inhibit differentiation of effector T-cell phenotype.
Keyphrases
- oxidative stress
- cell death
- endoplasmic reticulum stress
- induced apoptosis
- signaling pathway
- chronic obstructive pulmonary disease
- cell cycle arrest
- dendritic cells
- high fat diet induced
- transcription factor
- type diabetes
- metabolic syndrome
- peripheral blood
- working memory
- allergic rhinitis
- adipose tissue
- insulin resistance
- cell proliferation
- cystic fibrosis
- skeletal muscle
- newly diagnosed